ReviewCureus2025
Research Trends and Insights Regarding MicroRNAs in Psoriasis: A Comprehensive Analysis.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) have emerged as key regulators in psoriasis, yet the global research landscape has not been systematically mapped from an informatics and translational perspective. We searched the Web of Science Core Collection on April 23, 2024, for English-language articles and reviews using "TS=(psoriasis) AND TS=(miRNA OR miR)". Records and cited references were exported as TXT/BIB. Bibliometric and network analyses were performed with VOSviewer (v1.6.18, Leiden University, Leiden, Netherlands) and the bibliometrix package in R (v4.2.1, R Foundation for Statistical Computing, Vienna, Austria). Co-authorship, co-occurrence, and citation networks were constructed with predefined thresholds; local vs. global citations were distinguished. Protein-protein/miRNA-target interactions were summarized via STRING (version/date aligned with the bibliometric window). We identified 449 publications (393 articles, 56 reviews) from 2003 to 2024, with a 13.8% annual growth and 28.5 citations per document. Thematic mapping recovered basic themes (psoriasis, keratinocytes, inflammation), motor themes (miR-146a-5p, exosomes, GAB1), and emerging terms (STAT3, adalimumab). A STRING-based summary highlighted hubs (STAT3, PTEN, TRAF6) converging on inflammatory and proliferative pathways. Translational tags co-localized "biomarker/monitoring" with core psoriasis/miRNA clusters, and drug tokens (e.g., adalimumab) appeared in emerging/motor zones, indicating a literature focus that is potentially useful for panel scoping and exploratory endpoint selection. Research on miRNAs in psoriasis shows sustained growth and a shift toward translational topics. The evidence map and prioritized miRNA hubs can inform biomarker panel selection, trial design, and clinical decision support in psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.